Constipation occurs in 20-40% of GLP-1 users due to slower gastric emptying and reduced intestinal motility, making it one of the most common gastrointestinal side effects reported in clinical trials and real-world use
It wouldnt mean the peptides are FDA-approved, but it would mean they could be manufactured at compounding pharmacies, which would automatically make them safer. Considering Peptides
If symptoms persist beyond four to six weeks on a stable dose, discuss with your healthcare provider whether a dose reduction or slower titration schedule might help
Signs of bowel obstruction , such as severe constipation, inability to pass wind, progressive abdominal distension, or vomiting
This is particularly important for the growing community of researchers exploring GLP-1 microdosing for metabolic benefits without the dramatic appetite suppression and weight loss that higher doses produce